Selvita (WSE:SLV), a clinical stage drug discovery and development company focused on innovative medicines for oncology patients, will publish the most recent data from its oncology programs at the 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC), which will take place on November 7–11, 2018 at the Walter E. Washington Convention Center in Washington, D.C., USA.

Data presented at the conference will include recent results from Selvita’s discovery phase project targeting cancer immunometabolism – a dual A2A/A2B adenosine receptor antagonist, as well as cancer immunotherapy – a novel class of small molecule direct STING agonists.

"We look forward to present new results from our early discovery projects. We see our immunometabolism and immunooncology programs as key assets in Selvita’s pipeline. Therefore we are excited to share the data demonstrating potent, next-generation small molecule STING agonists as well as a series of dual A2A/A2B antagonists retaining its nanomolar potency in tumor-like adenosine rich environment" - said Krzysztof Brzózka, Chief Scientific Officer at Selvita.

The results from Selvita’s above-mentioned programs will be presented at the following poster sessions:

the poster presentation entitled: "Novel class of small molecule direct STING agonists as potential cancer immunotherapy", abstract no. P515, will take place on Friday, November 9, between 12:45 – 2:15 p.m. and 6:30 – 8 p.m., Hall E

the poster presentation entitled: "Characterization of novel dual A2A/A2B adenosine receptor antagonists for cancer immunotherapy", abstract no. P204, will take place on Saturday, November 10, between 12:20 – 1:50 p.m. and 7:00 – 8:30 p.m., Hall E

SITC 2018 brings together a unique and international mix of pharmaceutical and biotech companies, leading universities and clinical research institutions in the cancer immunotherapy area.  It provides a multidisciplinary educational and interactive environment focused on improving outcomes for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy.

Selvita Oncology Pipeline
In its internal research and development efforts, Selvita focuses on different dimensions of oncology. The company’s most advanced R&D program is SEL24, a dual PIM/FLT3 kinase inhibitor currently in Phase I/II clinical study, licensed to Menarini Group. The second most advanced program is SEL120, the first-in-class small molecule inhibitor of CDK8 with potential use in hematological malignancies, colorectal cancer and breast cancer, currently in IND-enabling studies. In August 2017 Selvita signed a partnering agreement with The Leukemia and Lymphoma Society for preclinical and Phase I clinical development of SEL120 in area of AML, within the Therapy Acceleration Program. Selvita early discovery programs are focused on a number of novel oncology targets in the area of kinase inhibitors, cancer metabolism & immunometabolism and immunooncology.

About Selvita
Selvita S.A. is a clinical stage drug discovery company engaged in the research and development of novel cancer therapies, as well as provision of integrated drug discovery services. Selvita is headquartered in Krakow, Poland, with offices in the USA (Greater Boston, San Francisco Bay), and in the UK (Cambridge). Selvita has currently several projects at early or late discovery stage. Drug discovery clients of Selvita include numerous large and medium-sized pharmaceutical and biotechnology companies from USA and Europe. The company is listed on the Warsaw Stock Exchange (WSE:SLV).